2024
Rare Breast Tumors
Harigopal M, Podany P, Andrejeva L, Singh K. Rare Breast Tumors. 2024, 343-374. DOI: 10.1007/978-3-031-65711-5_13.Peer-Reviewed Original ResearchSubtypes of breast cancerBreast cancerRare subtypeWorld Health OrganizationRare subtype of breast cancerHistological subtype of breast cancerWorld Health Organization Classification of TumorsCore needle biopsy specimensWorld Health Organization classificationTall cell carcinomaNeedle biopsy specimensRare histologic typeClassification of tumorsRare cancer typesRare tumorHistological subtypesHistological typeCell carcinomaUnusual subtypeBiopsy specimensPrognostic implicationsGenetic alterationsHistological featuresHistologic cluesAncillary testsRadiologic-Pathologic Correlation of Cardiac Tumors: Updated 2021 WHO Tumor Classification.
Lorca M, Chen I, Jew G, Furlani A, Puri S, Haramati L, Chaturvedi A, Velez M, Chaturvedi A. Radiologic-Pathologic Correlation of Cardiac Tumors: Updated 2021 WHO Tumor Classification. RadioGraphics 2024, 44: e230126. PMID: 38722782, DOI: 10.1148/rg.230126.Peer-Reviewed Educational MaterialsConceptsCardiac tumorsClassification of tumorsCardiac massWorld Health OrganizationCharacterization of cardiac massesWorld Health Organization Classification of TumorsWorld Health Organization tumor classificationWorld Health Organization classificationMalignant cardiac massesPrimary cardiac tumorsPrimary cardiac neoplasmsCardiac metastasisPapillary fibroelastomaThoracoabdominal CTCardiac CTCardiac neoplasmsIntracardiac massesNoncardiac indicationsSurgical managementRadiological investigationsTumor biologyTumor typesCardiac MRIAnatomical variantsTreatment planning
2021
Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors
Buza N. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Seminars In Diagnostic Pathology 2021, 39: 58-77. PMID: 34750021, DOI: 10.1053/j.semdp.2021.10.006.Peer-Reviewed Original ResearchConceptsGynecologic carcinomasOvarian carcinomaPathology evaluationLower genital tract carcinomaMismatch repair protein immunohistochemistryGenital tract carcinomaPD-L1 testingFemale genital tumorsLower genital tractSignificant prognostic differencesPrediction of prognosisRoutine pathology practiceClassification of tumorsMucinous adenocarcinomaPrognostic differencesEndometrial carcinomaHuman papillomavirusGenital tumorsProtein immunohistochemistryWHO classificationPrecursor lesionsGenital tractDiagnostic confirmationDifferential diagnosisImmunohistochemical markersThe 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ, Marino M, Marom EM, Moreira AL, Nicholson AG, Noguchi M, Nonaka D, Papotti MG, Porubsky S, Sholl LM, Tateyama H, Thomas de Montpréville V, Travis WD, Rajan A, Roden AC, Ströbel P. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? Journal Of Thoracic Oncology 2021, 17: 200-213. PMID: 34695605, DOI: 10.1016/j.jtho.2021.10.010.Peer-Reviewed Original ResearchConceptsThymic epithelial tumorsGerm cell tumorsCell tumorsMesenchymal neoplasmsWHO classificationEpithelial tumorsMediastinal germ cell tumorsLow tumor mutational burdenTumor mutational burdenNew tumor entityClear cell carcinomaPositron emission tomographyClassification of tumorsThymic EpithelialThymic carcinomaFifth editionB3 thymomaTargetable mutationsCell carcinomaMesenchymal tumorsMetaplastic thymomaImmunohistochemical characterizationClinical informationMutational burdenDiagnostic advances
2020
Diagnosis of digestive system tumours
Washington M, Goldberg R, Chang G, Limburg P, Lam A, Salto‐Tellez M, Arends M, Nagtegaal I, Klimstra D, Rugge M, Schirmacher P, Lazar A, Odze R, Carneiro F, Fukayama M, Cree I, Board W. Diagnosis of digestive system tumours. International Journal Of Cancer 2020, 148: 1040-1050. PMID: 32674220, DOI: 10.1002/ijc.33210.Peer-Reviewed Original ResearchConceptsDiagnosis of tumorsNeuroendocrine tumorsClassification of neuroendocrine tumorsWHO classification of tumorsLiquid biopsy resultsDysplasia to carcinomaWHO blue bookClassification of tumorsDigestive system tumorsBiopsy resultsWHO classificationGenetic abnormalitiesPrecancerous lesionsSystem tumorsBiliary tractMalignant processDiagnostic InnovationsCare of patientsTumorTreatment selectionClinical practiceOutcome predictionCarcinomaPatientsDiagnosisGastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours
Quezada‐Marín J, Lam A, Ochiai A, Odze R, Washington K, Fukayama M, Rugge M, Klimstra D, Nagtegaal I, Tan P, Arends M, Goldblum J, Cree I, Salto‐Tellez M. Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology 2020, 77: 340-350. PMID: 32320495, DOI: 10.1111/his.14120.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationWorld Health Organization Classification of TumorsMolecular biomarkersClassification of tumorsEpithelial neoplasmsDigestive tumorsRoutine diagnosticsDevelopment of drugsOncological pathologyArtificial intelligence toolsTumorIntelligence toolsBiomarkersMethod of classification
2016
Molecular Neuropathology and the Ontogeny of Malignant Gliomas
Huttner A. Molecular Neuropathology and the Ontogeny of Malignant Gliomas. 2016, 15-29. DOI: 10.1007/978-3-319-49864-5_2.Peer-Reviewed Original Research
2015
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K, Orazi A, Ströbel P. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. Journal Of Thoracic Oncology 2015, 10: 1383-1395. PMID: 26295375, PMCID: PMC4581965, DOI: 10.1097/jto.0000000000000654.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationThymic epithelial tumorsOrganization classificationEpithelial tumorsThymic squamous cell carcinomaPositron emission tomography/Squamous cell carcinomaGerm cell tumorsNew tumor entityEmission tomography/Soft tissue tumorsClassification of tumorsDendritic cellsMediastinal lymphomaThymic tumorsCell carcinomaCell tumorsThoracic surgeryTomography/Therapeutic decisionsThymus sectionsMyeloid neoplasmsTumor entitiesDiagnostic criteriaClinical relevance
2006
Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
Bhargava R, Chen B, Klimstra D, Saltz L, Hedvat C, Tang L, Gerald W, Teruya‐Feldstein J, Paty P, Qin J, Shia J. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006, 106: 1857-1862. PMID: 16532444, DOI: 10.1002/cncr.21782.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorPharmDx kitColorectal carcinomaStaining intensityImmunohistochemical detection of epidermal growth factor receptorEpidermal growth factor receptor statusEpidermal growth factor receptor expressionIntensity scoresGrowth factor receptor expressionScore 1Intensity of positive stainingDetection of epidermal growth factor receptorMedian staining intensityAnti-EGFR therapyMetastatic colorectal carcinomaScore categoriesSelection of patientsAutomated image-analysis systemGrowth factor receptorClassification of tumorsManual scoringEGFR-negativeAnti-EGFRReceptor expressionPharmDx
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply